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ABSTRACT
Aims To investigate the prognostic signiﬁcance of
macular capillary drop-out and previous panretinal laser
photocoagulation in diabetic macular oedema treated
with intravitreal ranibizumab.
Methods Retrospective observational case series.
Treatment-naive patients with diabetic macular oedema
that had been treated with intravitreal ranibizumab as
per the RESTORE study protocol for at least 12 months
were included. Some patients (n=15) had previous
panretinal laser photocoagulation. Best-corrected visual
acuity and central retina thickness were recorded
monthly. The foveal avascular zone and the perifoveal
capillaries were quantitatively and qualitatively assessed
on ﬂuorescein angiography on two occasions during the
observational period.
Results From the 46 eyes (46 patients) in this study,
13 (28%) had evidence of perifoveal capillary drop-out.
Central retinal thickness was signiﬁcantly thinner at
baseline (p=0.02) and throughout the study period in
these eyes compared with those with normal perifoveal
capillaries. Both groups responded with a signiﬁcant
gain of best-corrected visual acuity to ranibizumab
treatment (7.6±3.3 and 6.3±1.3 ETDRS letters,
respectively). Eyes with previous panretinal laser
photocoagulation displayed a comparable ﬁnal outcome
regarding function and morphology, requiring a similar
intensity of intravitreal injections.
Conclusions Perifoveal capillary drop-out did not limit
the gain of visual acuity from intravitreal ranibizumab
treatment. The reduction of central retina thickness was
similar to that seen in eyes with normal perifoveal
capillaries. Central retinal thickness in eyes with
perifoveal capillary drop-out was generally reduced.
However, this did not affect their beneﬁt from treatment.
Ranibizumab did not increase the amount of perifoveal
capillary loss.
INTRODUCTION
Diabetic retinopathy is the most common micro-
vascular pathology in patients with diabetes melli-
tus, and is the leading cause of blindness in
working aged adults in the industrialised world.1
Among patients with diabetic retinopathy, diabetic
macular oedema (DMO) is the most frequent cause
of visual impairment. It is an advanced vision-
limiting complication that affects nearly 30% of
patients who have suffered from diabetes mellitus
for at least 20 years.2
Prolonged hyperglycaemia, leading to chronic
retinal hypoxia, is the major driving force in the
development of DMO, a microvascular complica-
tion. The pathogenic mechanisms include
thickening of the basal membrane of retinal capillar-
ies and loss of perivascular pericytes. Chronic
retinal microvascular damage and hypoxia result in
elevation of intraocular levels of vascular endothe-
lial growth factor A (VEGF), a molecule that greatly
increases the permeability of blood vessels.3
Blockage of VEGF signalling has been shown to
restore macular anatomy and considerably improve
vision in several large randomised clinical trials.
Ranibizumab (Genentech, South San Francisco,
California, USA, and Novartis Schweiz, Basel,
Switzerland), a monoclonal antibody fragment that
binds to all isoforms of VEGF-A, has been shown to
increase best-corrected visual acuity (BCVA) signiﬁ-
cantly by 11–12.5 letters at month 24 and decrease
central retinal thickness (CRT) when injected
monthly as in the RISE and RIDE trials.4 Because
VEGF is also an important constitutional trophic
factor that is involved in endothelial proliferation
and neovascularisation,5 as well as retinal collateral
formation,6 and has been shown to increase blood
ﬂow in cerebral ischaemia,7 concerns have been
articulated that the elimination of VEGF could com-
promise retinal capillaries and worsen ischaemia.
However, despite some case reports showing
increased capillary loss after intravitreal anti-VEGF
treatment for DMO,8 a recent analysis of data from
the RIDE and RISE trials suggested that monthly
injections of ranibizumab might actually slow down
the natural progression of retinal non-perfusion.9
Given the pivotal role of VEGF in the formation
and exacerbation of DMO, it was our aim to investi-
gate whether capillary loss alters the beneﬁt from
pro re nata treatment, and whether previous panret-
inal laser photocoagulation (PRP) might enhance
the effect of anti-VEGF treatment.
MATERIALS AND METHODS
This was a single-centre retrospective observational
case series. Investigators adhered to the tenets of
the Declaration of Helsinki and Institutional
Review Board/Ethics Committee approval was
obtained for data collection and analysis (KEK-Nr.
093/13). The need for written consent from
patients was waived because of the retrospective
nature of the study. Study data were collected and
managed using REDCap (Research Electronic Data
Capture) hosted at our institution.10 REDCap is a
secure, web-based application designed to support
data management for research studies.
Participants
Adult patients with type 1 or 2 diabetes mellitus with
centre-involving DMO, diagnosed with spectral
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domain optical coherence tomography (SD-OCT) (Heidelberg
Spectralis, Heidelberg Engineering, Heidelberg, Germany) and
ﬂuorescein angiography, were assessed in this study (table 1).
Only treatment-naive eyes with at least 1 year of follow-up
were included from the Retina Service of the Department of
Ophthalmology at the University Hospital Bern, Switzerland.
Exclusion criteria were any of the following: uncontrolled glau-
coma, previous pars plana vitrectomy, evidence of focal macular
laser or a history of intravitreal steroids, intraocular surgery or
capsulotomy during the observational period. The loading
protocol was identical for all patients and consisted of three
monthly intravitreal injections of ranibizumab 0.5 mg/0.05 mL,
followed by monthly assessments including SD-OCTand further
intravitreal ranibizumab as needed. Macular rescue laser was not
used. The retreatment decision was based on the BCVA as per
RESTORE study criteria.11
Image acquisition
SD-OCT scans were acquired using an established protocol con-
sisting of both a crosshair and a volume scan. The volume scan,
covering 20°×20°, comprised 49 parallel B-scans separated by
120 μm, whereby each B-scan was the average of nine frames
(automated real-time repetition rate=9), each consisting of 512
A-scans. CRT was determined automatically by the software
(Heidelberg Eye Explorer, version 1.7.1.0, Heidelberg
Engineering, Heidelberg, Germany) as the distance from the
internal limiting membrane of the retina to the outer border of
the retinal pigment epithelium.
For ﬂuorescein angiography, 5 mL of 10% sodium ﬂuorescein
(Fluoresceine 10% Faure 0.5 g/5 mL, Novartis Pharma Schweiz,
Rotkreuz, Switzerland) was injected intravenously and images
were obtained with a confocal scanning laser ophthalmoscope
(Spectralis HRA, Heidelberg Engineering, Heidelberg, Germany).
Quantiﬁcation of central capillary loss and peripheral
diabetic retinopathy severity
The foveal avascular zone diameter, the perifoveal capillaries
and the severity of diabetic retinopathy were independently
assessed on ﬂuorescein angiography by two fellowship-trained
retina specialists (AE, MSZ) on two occasions during the obser-
vational period. Capillary loss in the central and the four inner
subﬁelds of the standard ETDRS grid (1, 3, 6 mm) was graded
on early-phase ﬂuorescein angiogram images as per the method
described in the ETDRS Report Number 11.12 In brief, a
grading was assigned to each of the ﬁve subﬁelds based on the
standard photographs 1A and 2 included in the aforementioned
original publication. The grading steps for capillary loss were 0
(absent), 1 (questionable), 2 (deﬁnitely present), 3 (moderate)
and 4 (severe). The maximum grade of capillary loss in any of
the ﬁve subﬁelds was then assigned as the ﬁnal grade to the eye
evaluated. Inter-rater agreement as quantiﬁed by Cohen’s kappa
was 0.91 (95% CI 0.82 to 1.00). If the grading differed
between assessors, the case was reviewed and discussed to reach
a common conclusion on the ﬁnal grade to be assigned.
Capillary drop-out was deemed present in eyes with a capillary
loss grading >1.
Similarly, in eyes without previous PRP, diabetic retinopathy
severity was classiﬁed into eight levels (table 2) according to the
ETDRS Report Number 12 protocol with slight modiﬁcations,
ranging from absent retinopathy (Level 10) to moderate prolife-
rative diabetic retinopathy (Level 65).13
For quantiﬁcation of the size of the foveal avascular zone, the
diameter of the outline of the foveal avascular zone was deter-
mined using the circle measurement tool available in the
Heidelberg Eye Explorer software (see online supplementary
ﬁgure for schematic illustration).
Statistical analysis
The last observation carried forward approach was used to sub-
stitute missing BCVA data at the ﬁnal visit. Statistical analysis
was performed using a standard software package (Prism 6,
GraphPad Software, La Jolla, California, USA) and R for Mac
OS X (R 3.1.2 GUI 1.65 Mavericks build). Unless indicated
otherwise, results are given as mean±SEM in the text.
Table 1 Demographics of patients at baseline
Mean age, years (SD) 63.5 (12.3)
Male, n (%) 33 (69)
Mean HbA1c, % (SD) 7.7 (1.5)
Mean systolic blood pressure, mm Hg (SD) 136 (15)
Mean diastolic blood pressure, mm Hg (SD) 76 (9)
Mean arterial blood pressure, mm Hg (SD) 96 (10)
Mean perifoveal capillary drop-out grading (SD) 1.5 (1.1)
Table 2 Diabetic Retinopathy Severity Score (DRSS) of patients
without previous PRP at baseline
Diabetic retinopathy severity DRSS level n (%)
Absent 10 1 (3.1)
Microaneurysms only 20 2 (6.3)
Mild NPDR 35 14 (43.8)
Moderate NPDR 43 5 (15.6)
Moderately severe NPDR 47 2 (6.3)
Severe NPDR 53 4 (12.5)
Mild PDR 61 2 (6.3)
Moderate PDR 65 2 (6.3)
NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy;
PRP, panretinal laser photocoagulation.
Figure 1 Best-corrected visual acuity (BCVA) and retinal thickness
over 12 months. (A) Mean change in BCVA ETDRS letter score from
baseline (BL) to month 12. (B) Mean change in central retinal thickness
(CRT) from BL to month 12.
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Depending on the distribution of the statistical sample, data
were analysed using the Pearson’s χ2 test and the paired or
unpaired Student’s t test with correction for multiple compari-
sons as needed. To rule out interference between the main out-
comes, diabetic retinopathy severity and capillary drop-out,
two-way ANOVA testing was conducted to assess the effects of
Diabetic Retinopathy Severity Score (DRSS) score and capillary
drop-out grading on ﬁnal BCVA and the average number of
intravitreal ranibizumab treatments per year. We did not ﬁnd
any interaction between the capillary drop-out grading and the
DRSS score, and the null hypothesis (independence) was not
rejected in the Fisher’s exact test (p=0.408).
A p value of less than 0.05 was considered statistically
signiﬁcant.
RESULTS
Forty eight patients that had started intravitreal ranibizumab
treatment for DMO between October 2010 and April 2013 at
the Retina Service of the Department of Ophthalmology at the
University Hospital Bern had data for 12 months. Two patients
with a foveal avascular zone diameter of more than 1500 μm
were excluded from the analysis to avoid distortion of the results
by macular ischaemia, which is usually associated with poor
visual prognosis. The mean age of the patients at the time of
Table 3 Comparison between eyes with and without capillary drop-out
Subjects with PRP IVTs per year (mean±SD) Baseline BCVA (mean±SD) CRT baseline (mean±SD) Retinal fluid at final visit
No capillary drop-out (n=27) 12 5.9±2.1 62.6±16.3 433±108 μm 88%
Capillary drop-out (n=13) 8 5.0±2.0 60.1±14.0 349±91 μm 90%
p Value 0.258* 0.203† 0.641† 0.020† 1.0*
*Pearson’s χ2 test with Yates’ continuity correction.†Two-sided unpaired Student’s t test.
BCVA, best-corrected visual acuity; CRT, central retinal thickness; IVT, intravitreal treatment; PRP, panretinal laser photocoagulation.
Figure 2 Outcomes for eyes with and without perifoveal capillary drop-out (CDO) of the macula. (A) Diameter of foveal avascular zone at baseline
(BL) in eyes with perifoveal CDO (capillary loss grading >1) and eyes with normal appearance of the perifoveal capillaries (NCDO; capillary loss
grading ≤1). (B) Central retinal thickness (CRT) at BL and 1 year after initiation of intravitreal treatment with ranibizumab. CRT was consistently
lower in eyes with CDO. (C) Mean improvement in best-corrected visual acuity (BCVA) and mean absolute ETDRS letters scores from BL to month 12
for both groups. (D) Mean decrease and mean absolute CRT for both groups from BL to month 12 (*p<0.05; Multiple t tests using the Holm–Sidak
method to correct for multiple testing; error bars in A and B represent SEM).
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diagnosis was 63.7 years (range 32–89 years). The baseline
characteristics of the study population are summarised in table 1.
The mean BCVA at baseline was 61.4±2.2 ETDRS letters and
increased to 68.3±2.1 letters at month 12 (p=0.0002). CRT
was 398±15 μm at baseline and 349±19 μm at month 12
(p=0.0001). On average, patients received 5.8±0.3 intravitreal
injections of ranibizumab (range 3–10) in the ﬁrst year of treat-
ment. The changes in BCVA and CRT in our patient cohort
during the ﬁrst 12 months were similar to other published data
and are summarised in ﬁgure 1.
While all 46 eyes had intraretinal ﬂuid (IRF) at baseline, only
four eyes (8.7%) had concomitant subretinal ﬂuid (SRF) at that
time. While after the three initial monthly injections SRF had
disappeared in all of these eyes, IRF persisted in 38 eyes (83%)
after the initiation phase. In 31 eyes (67%) IRF was present at
every monthly visit throughout the observational period.
Perifoveal capillary drop-out, CRT and BCVA
The ﬁndings from the comparison between eyes with capillary
drop-out and eyes with normal macular capillaries are sum-
marised in table 3.
The diameter of the foveal avascular zone at baseline was sig-
niﬁcantly larger in eyes with perifoveal capillary drop-out
(p=0.0005; unpaired t test; ﬁgure 2A). The initial CRT in the
capillary drop-out group was lower than in the eyes with
unaffected perifoveal capillary structure, and this difference per-
sisted throughout the observational period (ﬁgure 2B). The gain
in visual acuity was of similar magnitude for eyes with and
without perifoveal capillary drop-out (7.6±3.3 and 6.3±1.3
ETDRS letters, respectively; ﬁgure 2C). CRT reduction was
comparable in both groups (ﬁgure 2D). On ﬂuorescein angiog-
raphy, there was no evidence of deterioration or improvement
of the vascular structures in the central subﬁeld and the inner
ring of the ETDRS grid during the average 13 months period
between examinations (ﬁgure 3). Eyes with perifoveal capillary
drop-out needed by trend fewer intravitreal treatments than eyes
with unremarkable perifoveal capillaries (table 3).
PRP, CRT and BCVA
Twenty four eyes in the study population had advanced disease
requiring peripheral photoablation. While 15 eyes had received
PRP prior to anti-VEGF therapy for DMO (last treatment
Figure 3 Progression analysis of perifoveal capillary drop-out (CDO). Representative photographs of a macula at baseline (BL) (A) and after
17 months of treatment (B) with a constant CDO grading. The patient received in total ﬁve intravitreal ranibizumab injections. His diabetic
retinopathy was graded as ‘severe non-proliferative’ (level 53) and the CDO grading assigned was ‘questionable’ (grade 1). (C) Diameter of foveal
avascular zone at BL and follow-up (F/U) visit on ﬂuorescein angiography for eyes with CDO and normal perifoveal capillaries (NCDO). The mean
interval between BL and follow-up ﬂuorescein angiography was 13 months. The change of the foveal avascular zone diameter was not signiﬁcant
(paired Student’s t test; error bars represent SEM).
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31.0±10.1 months (range 6 weeks–12 years) before commence-
ment of intravitreal ranibizumab injections), 9 eyes received con-
comitant panretinal laser treatment during the observational
period. These nine eyes were excluded for the analyses investi-
gating the effects of previous PRP. Analysing the inﬂuence of
previous PRP on BCVA, CRT and the number of injections
needed, eyes with previous PRP (n=15) received by trend more
injections than eyes without previous peripheral laser treatment
(6.3±0.6 vs 5.2±0.4). However, the difference was not signiﬁ-
cant (p=0.187; unpaired t test with Welch’s correction). The
beneﬁt in ETDRS letter gain (ﬁgure 4B) was similar and the
reduction in CRTwas comparable in both groups (ﬁgure 4C).
DISCUSSION
The mean gain in BCVA (6.9±1.4 letters) from baseline to
month 12 in this series was similar to results reported in the
RESTORE study (6.8±0.8 letters), which used the same retreat-
ment criteria and studied a sample (n=116 in the ranibizumab
group) with comparable baseline mean BCVA (64.8±0.9). The
mean number of intravitreal ranibizumab injections needed to
achieve this result in our cohort (5.8 injections; median (range)
:6 (3-10)) was lower than in the RESTORE study (7.0 injections;
median (range) :7 (1-12); p=0.016). This dissimilarity in the
treatment intensity might be explained by the probably somewhat
greater macular thickness of subjects included in the RESTORE
study, which used time-domain OCT (Stratus, Carl Zeiss,
Meditec, Dublin, California, USA). In the current study SD-OCT
(Spectralis HRA+OCT, Heidelberg Engineering, Heidelberg,
Germany) was used, which has been reported to measure
macular thickness systematically 77 μm thicker than the Stratus
OCT.14 Hence, the mean CRT reported in the RESTORE study
of 427±118 (SD) μm should be corrected to 504 μm for com-
parison, which is signiﬁcantly different from the CRT of 398
±105 (SD) μm in the sample of the present study (p<0.0001).
In contrast to exudative age-related macular degeneration, the
persistence of IRF or SRF is generally not considered imminently
disconcerting in DMO. Nevertheless, the anatomical location of
ﬂuid collections seems to have an effect on function.
Photoreceptor outer segment disturbance has been linked to
impaired BCVA in DMO,15 and reduced retinal sensitivity was
found in the presence of SRF using microperimetry.16 There is
debate about the signiﬁcance of persistent ﬂuid on function and
prognostic implications for visual acuity. Excessive suppression
of VEGF, which at moderate levels is physiologically present in
the healthy retina,17 18 might harm the choroid and accelerate
progression of atrophy.19 In the pivotal RESTORE study, retinal
thickness and OCT-based assessment of the retina were
not included in the retreatment criteria that guided the adminis-
tration of intravitreal ranibizumab.11 The current study
applied the RESTORE criteria. The visual acuity gain for eyes
without recurrent or persistent retinal ﬂuid was slightly higher in
the subgroup analysis. IRF was very common and in two-thirds
of eyes was present at every monthly visit, which, however, does
not exclude the possibility that temporary resolution might have
occurred at early time points after treatment. In contrast, SRF
was found in less than 10% of eyes at baseline, and had resolved
completely in all eyes after the three initial monthly ranibizumab
injections. SRF was always seen in conjunction with IRF and
neither previous PRP nor the presence of capillary drop-out had
an inﬂuence on the occurrence of neurosensory detachments.
Concerns have also been raised as to whether chronic use of
anti-VEGF might further compromise retinal perfusion in eyes
with vascular disease.20 In the present study perifoveal capillary
loss did not negatively affect the beneﬁt from ranibizumab treat-
ment despite the fact that such retinas were consistently thinner,
and we did not ﬁnd any evidence for worsening of capillary
drop-out.
At ﬁrst glance counterintuitive is the observation that eyes
with previous PRP received by trend more intravitreal injections
Figure 4 Outcome analysis according to panretinal laser photocoagulation (PRP) status. (A) Colour fundus photographs at baseline (BL) and
month 12 as well as corresponding optical coherence tomography scans at BL, months 1, 5 and 12. (B) Best-corrected visual acuity (BCVA) letter
score from BL to month 12 for eyes without (no PRP) and with previous PRP. (C) Corresponding graph for central retinal thickness (CRT). Differences
were not statistically signiﬁcant at any time point (multiple t tests using the Holm–Sidak method to correct for multiple comparisons).
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than eyes without previous peripheral laser. VEGF, a major
driving force of macular oedema is known to be elevated in eyes
with diabetic retinopathy3 and there is debate about the role of
peripheral laser ablation in preventing or reducing DMO.21
Eyes that have had previous laser presumably have more
advanced peripheral microvascular disease, which in turn
increases the risk of diffuse macular oedema.22
In conclusion, perifoveal capillary drop-out did not limit gain
of visual acuity from intravitreal ranibizumab treatment. The
reduction of CRT was similar as in eyes with unremarkable
perifoveal capillaries. Interestingly, CRT in eyes with perifoveal
capillary drop-out was generally reduced. Ranibizumab did not
increase the amount of perifoveal capillary loss and the pres-
ence of peripheral laser scars from previous PRP did not
reduce the treatment intensity needed to achieve treatment
goals. The role of peripheral laser photoablation in the context
of anti-VEGF treatment for DMO in patients with non-
proliferative disease needs to be elucidated in larger prospective
trials.
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